Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Invested Capital (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Invested Capital for 15 consecutive years, with $16.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 50.78% to $16.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.1 million, a 50.78% decrease, with the full-year FY2025 number at $20.8 million, down 30.85% from a year prior.
  • Invested Capital was $16.1 million for Q4 2025 at Aytu Biopharma, down from $38.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $153.8 million in Q2 2021 to a low of $15.6 million in Q1 2021.
  • A 5-year average of $55.2 million and a median of $45.4 million in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: tumbled 83.38% in 2021, then skyrocketed 292.59% in 2022.
  • Aytu Biopharma's Invested Capital stood at $121.8 million in 2021, then plummeted by 50.06% to $60.8 million in 2022, then crashed by 45.92% to $32.9 million in 2023, then fell by 0.82% to $32.6 million in 2024, then tumbled by 50.78% to $16.1 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Invested Capital are $16.1 million (Q4 2025), $38.0 million (Q3 2025), and $20.8 million (Q2 2025).